Sepsis News and Research

Latest Sepsis News and Research

Hemicorporectomy effective, and add years and quality of life to survivors

A landmark, 25-year review of cases in which surgeons had to remove the lower portion of the body from the waist down for severe pelvic bone infections shows the therapy can add years and quality of life to survivors, say researchers at UT Southwestern Medical Center.

20 Nov 2009

FDA Advisory Committee votes in support of Pfizer's Prevnar 13

Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children.

19 Nov 2009

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. But a revolutionary new wound dressing developed at Tel Aviv University could cut that number dramatically.

18 Nov 2009

Financial results for third-quarter 2009 announced by Spectral Diagnostics

Spectral Diagnostics Inc., today announced its financial results for the third quarter ended September 30, 2009.

12 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

Physicians and researchers to develop kidney replacement device for children

When children need kidney dialysis because of disease or congenital defects, doctors are forced to adapt adult-size dialysis equipment. No FDA-approved kidney replacement devices exist that are specifically designed for children.

12 Nov 2009

Bayfront Medical Center to implement CareFocus clinical surveillance solution from Thomson Reuters

Bayfront Medical Center has selected Clinical Xpert CareFocus from Thomson Reuters as its clinical surveillance solution for improving Core Measures outcomes and patient safety indicator (PSI) scores while also supporting infection control and pharmacy intervention initiatives.

10 Nov 2009

"Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads" report from MarketResearch.com

MarketResearch.com has announced the addition of Kalorama Information's new report "Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads," to their collection of In Vitro Diagnostics market reports.

10 Nov 2009

Thomson Reuters releases CareFocus 2.0 clinical surveillance solution

Thomson Reuters today announced the newest release of Clinical Xpert(TM) CareFocus, a leading clinical surveillance solution that enables hospitals to identify at-risk patients in real-time and respond immediately to improve clinical quality and reduce total cost of treatment.

9 Nov 2009

'Hormone of darkness' melatonin regulates sleep effectively

Melatonin, a natural hormone segregated by the own human body, is an excellent sleep regulator expected to replace somniferous, which are much more aggressive, to correct the sleep/wakefulness pace when human biological clock becomes altered.

6 Nov 2009

Sirius Genomics signs its first Contribution Agreement with NRC-IRAP

Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed its first Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This research funding will be used to study genomic correlations in severe sepsis patients.

6 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Medela to host Virtual Human Milk Collection Campaign

Medela today announced it will host a Virtual Human Milk (breastmilk) Collection Campaign in honor of the March of Dimes' National Prematurity Awareness Month and the thousands of dedicated Neonatal healthcare professionals nationwide.

2 Nov 2009

36-month demonstration program at UCSF reports an 87.7% reduction in medication errors

A 36-month demonstration program at the University of California San Francisco (UCSF) reported this week an 87.7% reduction in medication administration errors – increasing medication administration accuracy to 98% at six Bay Area hospitals.

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

Quintiles and Eisai partner to develop potential oncology products

Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.

31 Oct 2009

Left side grafting has lower risk to donors; small graft size not the only cause of 'small-for-size graft syndrome'

A recent study by doctors at Shinshu University, School of Medicine, in Japan determined that left side grafting has lower risk to donors compared to grafts taken from the right lobe, and it appears to be the procedure of choice for adult-to-adult living donor liver transplantation (LDLT).

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

MSC's Quality Initiative Programs to support best practice-based training for healthcare professionals

MSC's Sepsis Program has demonstrated the capability to increase tested knowledge in early identification and treatment of sepsis among trainees by over 46 percent. The program has been delivered to healthcare providers representing a range of institutions, from community hospitals to large academic teaching hospitals, demonstrating wide applicability among healthcare professionals with varied clinical backgrounds and previous training.

30 Oct 2009

Sepsis News and Research

Latest Sepsis News and Research

Hemicorporectomy effective, and add years and quality of life to survivors

FDA Advisory Committee votes in support of Pfizer's Prevnar 13

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Financial results for third-quarter 2009 announced by Spectral Diagnostics

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Physicians and researchers to develop kidney replacement device for children

Bayfront Medical Center to implement CareFocus clinical surveillance solution from Thomson Reuters

"Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads" report from MarketResearch.com

Thomson Reuters releases CareFocus 2.0 clinical surveillance solution

'Hormone of darkness' melatonin regulates sleep effectively

Sirius Genomics signs its first Contribution Agreement with NRC-IRAP

Interim data from Schering-Plough's narlaprevir Phase IIa study

Medela to host Virtual Human Milk Collection Campaign

36-month demonstration program at UCSF reports an 87.7% reduction in medication errors

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Quintiles and Eisai partner to develop potential oncology products

Left side grafting has lower risk to donors; small graft size not the only cause of 'small-for-size graft syndrome'

Eisai reports global Phase III study results of eribulin mesylate

MSC's Quality Initiative Programs to support best practice-based training for healthcare professionals

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Sepsis News and Research

Latest Sepsis News and Research

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in